Seemal Desai, MD, FAAD

This episode, titled Future Directions in Vitiligo: Emerging Therapies and Patient-Centered Care, features Dr. Desai discussing the following critical questions:

In Emerging Role of Oral JAK Inhibition in Vitiligo Management, Dr. Desai delves into the following critical questions:

In this episode, Long-Term Repigmentation Outcomes and Real-World Use of Ruxolitinib Cream, Dr. Desai explores the following questions:

Welcome back to another Managed Healthcare Executive Population Health Perspectives series. In this episode titled, Clinical Impact of JAK Inhibition in Vitiligo: Efficacy, Repigmentation, and Safety Insights, Dr. Seemal Desai led the conversation about the following questions: Which inflammatory chemokines associated with melanocyte destruction are reduced with JAK inhibition? What percentage of patients achieved F-VASI75 at week 24 in the TRuE-V1 and TRuE-V2 trials? What improvements in repigmentation were observed after 52 weeks of treatment with ruxolitinib cream? What were the most commonly reported adverse events associated with ruxolitinib cream in clinical trials and how are you monitoring/managing these?

Seemal Desai, M.D., FAAD, discusses how effective patient education and engagement strategies, combined with emerging telemedicine and digital health technologies, enhance vitiligo care delivery, disease monitoring and patient self-management capabilities.

The panelist discusses how vitiligo’s psychological and social impacts significantly affect patients’ quality of life and treatment adherence, necessitating a holistic approach that addresses both physical symptoms and psychosocial support needs.

Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through updated formulary decisions and treatment algorithms while addressing insurance coverage barriers and balancing treatment aggressiveness with value-based care considerations.

Seemal Desai, M.D., FAAD, discusses how treatment safety and effectiveness must be carefully evaluated through monitoring clinical outcomes and patient-reported measures, with special consideration given to unique challenges in vulnerable populations like children, pregnant women and those with comorbidities, where treatment approaches require careful modification to balance efficacy and safety concerns.

The panelist discusses how emerging targeted therapies like Janus kinase inhibitors and combination treatment approaches are transforming vitiligo management, with treatment selection guided by disease patterns, progression rates and individual patient response, while acknowledging the need for systematic assessment and alternative strategies for treatment-resistant cases.

Seemal Desai, M.D., FAAD, discusses how immune system dysregulation and genetic variants intersect to trigger vitiligo development while highlighting diagnostic challenges including identifying disease subtypes and distinguishing vitiligo from other depigmentation disorders.